Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MB | P02144 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21053191 | 0.79 | PDE3B (0.42) | PDE3BPDE3A | |
| SCHEMBL21054030 | 0.76 | CYP11B1 (0.33) | MBCYP11B1CYP11B2 | |
| SCHEMBL22686131 | 0.76 | MGAM (0.30) | — | |
| SCHEMBL21054112 | 0.74 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL22717184 | 0.73 | EHMT2 (0.37) | — | |
| SCHEMBL22717228 | 0.71 | NNMT (0.35) | — | |
| SCHEMBL22686155 | 0.70 | CA12 (0.39) | — | |
| SCHEMBL22717074 | 0.70 | EHMT2 (0.33) | — | |
| SCHEMBL22717065 | 0.70 | HTT (0.33) | — | |
| SCHEMBL3352684 | 0.68 | PDE3B (0.42) | MBPDE3BPDE3ACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
| CN-111741964-A | Heterocyclic compounds as PRMT5 inhibitors | 安杰斯制药公司 | 2020-10-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | MB 3634/4885PDE3B 1119/4885PDE3A 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.